We Venture Capital, the corporate venture capital operation of Werfen, announces its launch today
We Venture Capital is the venture capital arm of Werfen, committed to investing in diagnostics start-ups, as well as digital solutions and biotechnology, surrounding the diagnostics space.
Through a global reach, We Venture Capital invests primarily in Series A, and may also invest in Seed or Series B. With an early-stage focus, investments target start-ups close to market, or early market entrants ready to scale up.
We Venture Capital actively partners with its portfolio companies and supports their growth by leveraging its knowledge of diagnostics worldwide.
Having an evergreen structure allows We Venture Capital to partner with portfolio companies to create long-term value all the way to the optimal point of exit.
We Venture Capital is further proof of Werfen’s commitment to the advancement of patient care through innovation. This vehicle allows Werfen to invest in early-stage companies, understand trends in healthcare, and be at the forefront of disruptive technologies that will shape the future of diagnostics.
Javier Gomez, Chief Financial Officer, Werfen
Our investment team is truly passionate about partnering with start-ups that drive change and technological disruption in the diagnostics field, and we aim to become a leader in diagnostic venture capital. We want to thank everyone who has supported this launch and for bringing We Venture Capital to life.
Louise Warme, Head of We Venture Capital
We Venture Capital currently holds two portfolio companies, operating in diagnostics. Visit our Portfolio page for more information.